Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Doxifluridine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.90 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.90 |
| ▸ | TSHR | P16473 | 1/20 | 0.90 |
| ▸ | MAPT | P10636 | 1/20 | 0.90 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.90 |
| ▸ | HBB | P68871 | 1/20 | 0.90 |
| ▸ | P2RY6 | Q15077 | 4/20 | 0.58 |
| ▸ | P2RY14 | Q15391 | 4/20 | 0.58 |
| ▸ | NT5E | P21589 | 1/20 | 0.58 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.46 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Doxifluridine SCHEMBL2553189 | 1.00 | LMNA (0.90) | LMNASMN1; SMN2TSHRMAPTPMP22 | |
| Doxifluridine SCHEMBL14291576 | 0.95 | LMNA (1.00) | LMNASMN1; SMN2TSHRMAPTPMP22 | |
| Doxifluridine SCHEMBL12932255 | 0.95 | LMNA (1.00) | LMNASMN1; SMN2TSHRMAPTPMP22 | |
| Doxifluridine SCHEMBL4932137 | 0.95 | LMNA (1.00) | LMNASMN1; SMN2TSHRMAPTPMP22 | |
| Doxifluridine SCHEMBL98005 | 0.95 | LMNA (1.00) | LMNASMN1; SMN2TSHRMAPTPMP22 | |
| Doxifluridine SCHEMBL8095 | 0.95 | LMNA (1.00) | LMNASMN1; SMN2TSHRMAPTPMP22 | |
| Doxifluridine SCHEMBL8094 | 0.95 | LMNA (1.00) | LMNASMN1; SMN2TSHRMAPTPMP22 | |
| Doxifluridine SCHEMBL14564897 | 0.95 | LMNA (1.00) | LMNASMN1; SMN2TSHRMAPTPMP22 | |
| Doxifluridine SCHEMBL15060572 | 0.95 | LMNA (1.00) | LMNASMN1; SMN2TSHRMAPTPMP22 | |
| Doxifluridine SCHEMBL10079621 | 0.95 | LMNA (1.00) | LMNASMN1; SMN2TSHRMAPTPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2552453-A2 | METHODS AND COMPOSITIONS FOR TREATING OR AMELIORATING CANCER USING GEMCITABINE-5'-ELAIDATE | Clavis Pharma ASA (NO) | 2013-02-06 | — | — | EP | disclosed |
| US-20130005678-A1 | Methods and Compositions for Treating or Ameliorating Cancer Using Gemcitabine-5'-Elaidate | CLAVIS PHARMA ASA (NO) | 2013-01-03 | — | — | US | disclosed |
| WO-2011121453-A2 | METHODS AND COMPOSITIONS FOR TREATING OR AMELIORATING CANCER USING GEMCITABINE-5'-ELAIDATE | CLAVIS PHARMA ASA (NO) | 2011-10-06 | — | — | WO | disclosed |
| WO-2006102533-A2 | PHARMACEUTICALLY ACTIVE LIPID-BASED FORMULATION OF NUCLEOSIDE-LIPID CONJUGATES | NEOPHARM, INC. (US) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005678-A1 | Methods and Compositions for Treating or Ameliorating Cancer Using Gemcitabine-5'-Elaidate | SLC29A1, NUDT1, SLC29A2 | LMNA 2677/4885SMN1; SMN2 2683/4885TSHR 3642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.